MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $7.2840 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. MaxCyte had a negative net margin of 135.14% and a negative return on equity of 22.15%. The firm had revenue of $6.76 million during the quarter, compared to analyst estimates of $9.16 million. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Performance

MaxCyte stock opened at $0.84 on Friday. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $1.16. MaxCyte has a 52 week low of $0.64 and a 52 week high of $2.47. The firm has a market capitalization of $90.34 million, a price-to-earnings ratio of -1.96 and a beta of 1.37.

Institutional Investors Weigh In On MaxCyte

A number of institutional investors have recently modified their holdings of MXCT. Prudential Financial Inc. acquired a new stake in shares of MaxCyte during the 2nd quarter valued at $26,000. State of Wyoming acquired a new stake in shares of MaxCyte during the 2nd quarter valued at $38,000. Jain Global LLC acquired a new stake in shares of MaxCyte during the 4th quarter valued at $45,000. BNP Paribas Financial Markets lifted its stake in shares of MaxCyte by 266.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after purchasing an additional 18,913 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of MaxCyte in the 4th quarter valued at $67,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

Analyst Upgrades and Downgrades

MXCT has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Friday, April 24th. Wall Street Zen lowered shares of MaxCyte from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Finally, Craig Hallum decreased their target price on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, MaxCyte currently has an average rating of “Hold” and an average price target of $5.50.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.